# OnCo record primary-mediastinal-b-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "primary-mediastinal-b-cell-lymphoma" ;
  schema:name "Primary mediastinal (thymic) large B-cell lymphoma"@en ;
  schema:alternateName "PMBCL"@en, "PMBL"@en, "Primary mediastinal large B-cell lymphoma"@en, "Thymic large B-cell lymphoma"@en, "Mediastinal grey zone lymphoma (related)"@en ;
  schema:description "Primary mediastinal B-cell lymphoma is a fast-growing lymphoma of the thymus behind the breastbone that mostly affects young women. Immunochemotherapy cures about nine in ten, radiotherapy can now be skipped when the end-of-treatment scan is clear, and PD-1 antibodies and CAR-T cells rescue many of those who relapse."@en ;
  schema:url <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Primary_mediastinal_B-cell_lymphoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Primary_mediastinal_B-cell_lymphoma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/cd79b/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:terms <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/keynote-170/>, <https://onco.cc/trials/ielsg37/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/> ;
  onco:people <https://onco.cc/people/wyndham-wilson/> ;
  onco:pipeline <https://onco.cc/trials/ielsg37/>, <https://onco.cc/trials/keynote-170/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/trials/ielsg37/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-170/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/technologies/car-t/> .